VJOncology is committed to improving our service to you

ELCC 2019 | Updates from the PROFILE 1001 study

VJOncology is committed to improving our service to you

Alice Tsang Shaw

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital Boston, MA, presents updates from the PROFILE 1001 trial (NCT00585195) that looks at crizotinib for advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Dr Shaw describes that both overall and median survival was significantly prolonged than with current therapies. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter